Skip Navigation


Rheumatology Advance Access originally published online on May 20, 2008
Rheumatology 2008 47(7):1104-1105; doi:10.1093/rheumatology/ken175
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/7/1104    most recent
ken175v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pepper, R. J.
Right arrow Articles by Salama, A. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pepper, R. J.
Right arrow Articles by Salama, A. D.
Related Collections
Right arrow Pharmacology
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production

R. J. Pepper1, M. A. Fabre1, C. Pavesio2, G. Gaskin1, R. B. Jones3, D. Jayne3, C. D. Pusey1 and A. D. Salama1

1Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, 2Moorfields Eye Hospital, London and 3Renal Unit, Addenbrooke's Hospital, Cambridge, UK

Correspondence to: A. D. Salama, Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, Ducane Road, London W12 0NN, UK. E-mail: A.salama@imperial.ac.uk

The first 10% of the full text of this article appears below.

SIR, Churg–Strauss syndrome (CSS) is a necrotizing small-vessel vasculitis characterized by eosinophil recruitment and inflammation. IL-5 is a Th2 cytokine implicated in the pathogenesis of CSS by mediating eosinophil maturation, chemotaxis and adhesion to the vascular endothelium. Elevated levels of IL-5 are found in patients with active CSS, demonstrating that T-cell activation correlates with disease activity [1, 2]. Traditionally, treatment of CSS has consisted of immunosuppression with corticosteroids, and in more severe cases, the addition of agents such as AZA or cyclophosphamide . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?